BiotechTube

Lemborexant + placebo

ApprovedRecruiting
0 watching 0 views this week🔥 Hot
85
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Parkinson's Disease

Conditions

Parkinson's Disease, Insomnia, Motor Disorder

Trial Timeline

Mar 19, 2026 → Dec 1, 2026

NCT ID
NCT07384429

About Lemborexant + placebo

Lemborexant + placebo is a approved stage product being developed by Eisai for Parkinson's Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07384429. Target conditions include Parkinson's Disease, Insomnia, Motor Disorder.

Hype Score Breakdown

Clinical
30
Activity
20
Company
10
Novelty
10
Community
12

Clinical Trials (4)

NCT IDPhaseStatus
NCT07384429ApprovedRecruiting
NCT06874855ApprovedRecruiting
NCT04549168Phase 3Completed
NCT02952820Phase 3Completed

Competing Products

20 competing products in Parkinson's Disease

See all competitors
ProductCompanyStageHype Score
UB-312 + PlaceboVaxxinityPhase 1
25
NAV5001 + DaTscanNavidea BiopharmaceuticalsPhase 3
69
piclozotan + 0.9% sodium chloride (normal saline)Daiichi SankyoPhase 2
52
E2007EisaiPhase 3
77
ARICEPTEisaiPhase 3
77
PerampanelEisaiPhase 3
77
GPI 1485EisaiPhase 2
52
E2007EisaiPhase 3
77
Prior Donepezil 5mg + Prior Donzepezil 10mg + Prior PlaceboEisaiPhase 3
77
perampanel + placeboEisaiPhase 2
52
Placebo + E2007 + E2007EisaiPhase 3
77
E2007 + E2007 + E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
E2007EisaiPhase 2
52
2 mg perampanel + 4 mg perampanel + placebo comparatorEisaiPhase 3
77
Istradefylline (KW-6002)Kyowa KirinPhase 2
52
Istradefylline 20 mg or 40 mgKyowa KirinPhase 3
77
Istradefylline (KW-6002)Kyowa KirinPhase 3
77
PerampanelEisaiPhase 2
52

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85